Navigation Links
FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
Date:1/18/2008

- INTELENCE is the first NNRTI to show antiviral activity in patients with

NNRTI-resistant virus -

BRIDGEWATER, N.J., Jan. 18 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has granted accelerated approval to the anti-HIV medication INTELENCE (etravirine) tablets -- the first non-nucleoside reverse transcriptase inhibitor (NNRTI) to show antiviral activity in treatment- experienced adult patients with HIV resistant to a NNRTI and other antiretroviral (ARV) agents. INTELENCE, also known as TMC125, was developed by Tibotec Pharmaceuticals, Ltd. and will be marketed in the U.S. by Tibotec Therapeutics, a division of Ortho Biotech Products, L.P.

"NNRTIs have been used in HIV combination therapy for more than a decade, but their use has been limited by cross-resistance within the class. Resistance to one NNRTI generally meant resistance to all NNRTIs," said Richard Haubrich, M.D., Professor of Medicine, Division of Infectious Diseases, University of California, San Diego, and investigator in the INTELENCE Phase 3 DUET studies. "Etravirine breaks new ground in the NNRTI class, and provides a new option to thousands of treatment-experienced patients with NNRTI-resistant HIV."

INTELENCE, in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adult patients, who have evidence of viral replication and HIV-1 strains resistant to a NNRTI and other ARV agents.

This indication is based on Week 24 analyses from two randomized, double-blind, placebo-controlled trials of INTELENCE. Both studies were conducted in clinically advanced, three-class antiretroviral (NNRTI, N[t]RTI, PI) treatment-experienced adults.

The following points should be considered when initiating therapy with INTELENCE:

-- Treatment history and, when available, resistance testing, should guide


'/>"/>

SOURCE Tibotec Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
2. FDA Approves New Mechanism of Action Labeling for Ranexa(R)
3. FDA Approves Diovan(R) for Treatment of High Blood Pressure in Children
4. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
5. FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
6. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
7. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
8. FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
9. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
10. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
11. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... This webinar will focus on EMA ... assessment in biosimilars. , Regulatory frameworks are evolving many ... however the complex nature of biopharmaceuticals makes the demonstration ... extremely challenging. Based on the specific aspects of biosimilar ...
(Date:1/15/2014)... Two champions of science, technology, engineering, and ... annual competition for middle and high school students designed ... study. The competition presents students with real-world problems experienced ... Mathematics, and Sciences is a program administered by ...
(Date:1/15/2014)... 2013 was a banner year of continued ... saw continued independent research led by the team at ... $1 million grant from the Susanne Marcus Collins Foundation, ... peer reviewed journal, Amy Grant highlighted Brainwave Optimization® in ...
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... ERT (Nasdaq: ERES ), a leading provider of ... biopharmaceutical, medical device, and related industries, announced today that it ... Thursday, October 29, 2009 after the market closes. After the ... PM EDT that day. , For the conference call, ...
... A faster tool for cell programming and a new ... grand prizes of the 2009 Collegiate Inventors Competition, a program ... Abbott Fund, the non-profit foundation of the global health care ... (USPTO). Harris Wang, who invented a new way of ...
... 21 BioWa, Inc. (BioWa) and NKT Therapeutics, ... into an agreement which provides NKTT with access ... development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies. ... research, develop, manufacture and commercialize antibodies targeting natural ...
Cached Biology Technology:ERT to Announce 2009 Third Quarter Results on October 29, 2009 2Winners Announced in 2009 Collegiate Inventors Competition(R) 2Winners Announced in 2009 Collegiate Inventors Competition(R) 3Winners Announced in 2009 Collegiate Inventors Competition(R) 4Winners Announced in 2009 Collegiate Inventors Competition(R) 5Winners Announced in 2009 Collegiate Inventors Competition(R) 6Winners Announced in 2009 Collegiate Inventors Competition(R) 7BioWa and NKTT Announce Licensing of BioWa's POTELLIGENT(R) Technology For Use in Antibody Research and Development 2BioWa and NKTT Announce Licensing of BioWa's POTELLIGENT(R) Technology For Use in Antibody Research and Development 3
(Date:4/17/2014)... and pathogens that devastate honeybees in Europe, Asia and ... do not appear to be impacting native honeybee populations ... researchers., The invasive pests include including Nosema microsporidia ... honeybees appear to be resilient to these invasive pests, ... control pests in Europe, Asia and the United States ...
(Date:4/17/2014)... many serious conditions such as heart disease, epilepsy and ... therapies. Unfortunately, there is still much scientists do not ... and unexpected insight into the structure of sodium channels ... - which are responsible for ,fine-tuning, the activity of ... recent edition of the Journal of Biological Chemistry ...
(Date:4/17/2014)... Ind. -- Indiana University researchers have detected new early-warning ... diabetes. This discovery could have far-reaching implications for the ... care of over 25 million Americans. , "We had ... retinas at such early stages," said Ann Elsner, professor ... and lead author of the study. "We set out ...
Breaking Biology News(10 mins):East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3Structure of sodium channels different than previously believed 2New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3
... a commercially viable method for mass producing effective vaccines ... the months required for traditional egg-based vaccines. They report ... , The next flu pandemic could happen any time," ... (PSC) and a researcher on the study. "The ...
... click as Cornell University researchers have fabricated a set ... receptors on cell membranes and trigger larger-scale responses within ... an allergic response. , How cell membranes control cellular ... However, nanotechnology now gives researchers new tools to understand ...
... Not all biological weapons are created equal. They are ... agents being the scariest: They are easy to spread, ... pubic health system. One of these worrisome organisms is ... media attention. But work in Vince Fischetti's laboratory at ...
Cached Biology News:New influenza vaccine takes weeks to mass produce 2'Nano-keys' bind cell receptors and trigger allergic reactions 2'Nano-keys' bind cell receptors and trigger allergic reactions 3Newly discovered protein kills anthrax bacteria by exploding their cell walls 2
... Avian Myeloblastosis Virus Reverse Transcriptase (AMV RT) ... DNA, RNA or RNA:DNA hybrids (1). It ... efficient than RNA primers) as well as ... intrinsic RNase H activity. Both nonionic detergents ...
DNase I (Deoxyribonuclease I) digests single- and double-stranded DNA to oligodeoxyribonucleotides. Ribonuclease activity has been reduced to non-detectable levels....
... is a preparation of deoxyribonuclease I ... to produce 3-hydroxyl oligonucleotides. This preparation ... where maintaining the integrity of RNA ... for use with the Core Footprinting ...
... Liquid. In 100 mM KCl, 20 ... 20% glycerol, pH 7.9. AVOID FREEZE/THAW CYCLES. Human ... protein of 765 amino acids encoded by a ... positive and negative supercoiled DNAs without the requirement ...
Biology Products: